Apitope

Apitope is a clinical-stage biotechnology company founded in 2002, based in Diepenbeek, Belgium, with a subsidiary in Bristol, UK.

The company specializes in developing first-in-class antigen-specific immunotherapeutics aimed at treating autoimmune and allergic diseases. Apitope utilizes a proprietary discovery platform to create peptide-based therapies known as "apitopes®," which help restore immune system balance without causing global immune suppression. The company's lead product candidates include ATX-MS-1467 for Multiple Sclerosis and ATX-GD-59 for Graves' Disease, both of which are in clinical development. Apitope also has a robust pipeline targeting conditions such as Uveitis, Factor VIII Inhibitors, Myocarditis, Rheumatoid Arthritis, Type I Diabetes, and common allergies. Additionally, Apitope is working on novel diagnostic products for early detection of autoimmune diseases. The company aims to improve the quality of life for patients suffering from chronic disorders while minimizing the risks associated with traditional immune-suppressing therapies.